1. Dauw J, Martens P, Mullens W. CRT Optimization: What Is New? What Is Necessary? Curr Treat Options Cardiovasc Med. 2019;21(9):45. doi:10.1007/s11936-019-0751-2.
2. Alraies MC, Buchanan K, Waksman R. CRT 2017 late-breaking trials. Cardiovasc Revasc Med. 2017;18(4):304-7. doi:10.1016/j.carrev.2017.04.014.
3. Santangeli P, Di Biase L, Pelargonio G, et al. Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2011;32(2):125-35. doi:10.1007/s10840-011-9584-y.
4. Daubert C, Behar N, Martins RP, et al. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38(19):1463-72. doi:10.1093/eurheartj/ehw270.
5. Mullens W, Verga T, Grimm RA, et al. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol. 2009;53(7):600-7. doi:10.1016/j.jacc.2008.08.079.
6. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281-329. doi:10.1093/europace/eut206.
7. Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ Heart Fail. 2013;6(3): 427-34. doi:10.1161/CIRCHEARTFAILURE.112.000078.
8. Singh JP, Berger RD, Doshi RN, et al. Rationale and design for ENHANCE CRT: QLV implant strategy for non-left bundle branch block patients. ESC Heart Fail. 2018;5(6): 1184-90. doi:10.1002/ehf2.12340.
9. Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13(1):29. doi:10.1186/1532-429X-13-29.
10. Sommer A, Kronborg MB, Norgaard BL, et al. Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Eur J Heart Fail. 2016;18(11):1365-74. doi:10.1002/ejhf.530.
11. Lund LH, Svennblad B, Dahlstrom U, et al. Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. Eur J Heart Fail. 2018;20(4):769-7. doi:10.1002/ejhf.929.
12. Fatemi M, Le Gal G, Blanc JJ, et al. The use of epicardial electrogram as a simple guide to select the optimal site of left ventricular pacing in cardiac resynchronization therapy. Cardiol Res Pract. 2011:956062. doi:10.4061/2011/956062.
13. Gold MR, Birgersdotter-Green U, Singh JP, et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011;32(20):2516-24. doi:10.1093/eurheartj/ehr329.
14. Polasek R, Kucera P, Nedbal P, et al. Local electrogram delay recorded from left ventricular lead at implant predicts response to cardiac resynchronization therapy: retrospective study with 1 year follow up. BMC cardiovascular disorders. 2012;12:34. doi:10.1186/1471-2261-12-34.
15. Kosztin A, Kutyifa V, Nagy VK, et al. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients. Europace. 2016;18(4):550-9. doi:10.1093/europace/euv117.
16. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694-701. doi:10.1056/NEJMoa1401426.
17. Schouten O, Hoeks SE, Goei D, et al. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery. Journal of Vascular Surgery. 2009;49(2):435-42. doi:10.1016/j.jvs.2008.08.063.
18. Abraham WT, Young JB, León AR, et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110(18):2864-8. doi:10.1161/01.CIR.0000146336.92331.D1.